This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Jun;212(6):695-6.

doi: 10.1016/j.ajog.2015.02.004.

Neoadjuvant chemotherapy vs primary debulking surgery for advanced ovarian cancer. What is the debate regarding the ideal treatment: approach? age? or cost?

Affiliations

PMID: 26042956
DOI: 10.1016/j.ajog.2015.02.004

Editorial

Neoadjuvant chemotherapy vs primary debulking surgery for advanced ovarian cancer. What is the debate regarding the ideal treatment: approach? age? or cost?

Ritu Salani. Am J Obstet Gynecol. 2015 Jun.

. 2015 Jun;212(6):695-6.

doi: 10.1016/j.ajog.2015.02.004.

Author

Affiliation

¹ The Ohio State University, Columbus, OH. Electronic address: Ritu.salani@osumc.edu.

PMID: 26042956
DOI: 10.1016/j.ajog.2015.02.004

No abstract available

PubMed Disclaimer

Comment on

Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR, Lesnock JL, Farris C, Kelley JL, Krivak TC. Rowland MR, et al. Am J Obstet Gynecol. 2015 Jun;212(6):763.e1-8. doi: 10.1016/j.ajog.2015.01.053. Epub 2015 Jan 31. Am J Obstet Gynecol. 2015. PMID: 25644442 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information